RU2018124993A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018124993A3 RU2018124993A3 RU2018124993A RU2018124993A RU2018124993A3 RU 2018124993 A3 RU2018124993 A3 RU 2018124993A3 RU 2018124993 A RU2018124993 A RU 2018124993A RU 2018124993 A RU2018124993 A RU 2018124993A RU 2018124993 A3 RU2018124993 A3 RU 2018124993A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510908329 | 2015-12-09 | ||
| CN201510908329.2 | 2015-12-09 | ||
| PCT/CN2016/109079 WO2017097234A1 (en) | 2015-12-09 | 2016-12-08 | Inhibitors of influenza virus replication, application methods and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018124993A RU2018124993A (ru) | 2020-01-14 |
| RU2018124993A3 true RU2018124993A3 (enExample) | 2020-02-05 |
| RU2737190C2 RU2737190C2 (ru) | 2020-11-25 |
Family
ID=59012608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018124993A RU2737190C2 (ru) | 2015-12-09 | 2016-12-08 | Ингибиторы репликации вируса гриппа, способы их применения и использование |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10717732B2 (enExample) |
| EP (1) | EP3362451B1 (enExample) |
| JP (1) | JP6952695B2 (enExample) |
| KR (1) | KR102671350B1 (enExample) |
| CN (2) | CN106854205B (enExample) |
| AU (1) | AU2016368317B2 (enExample) |
| RU (1) | RU2737190C2 (enExample) |
| SG (1) | SG11201804225PA (enExample) |
| WO (1) | WO2017097234A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106854205B (zh) * | 2015-12-09 | 2019-07-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| CN109071567B (zh) * | 2016-05-19 | 2021-03-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
| WO2018033082A1 (en) | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| RU2727772C1 (ru) * | 2016-09-05 | 2020-07-23 | Гуандун Рэйновент Байотек Ко., Лтд. | Производные пиримидина против вируса гриппа |
| EP3555095B1 (en) | 2016-12-15 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US11098042B2 (en) | 2017-01-05 | 2021-08-24 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| PH12019502376B1 (en) | 2017-04-24 | 2024-06-05 | Cocrystal Pharma Inc | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
| CN109384783A (zh) * | 2017-08-09 | 2019-02-26 | 银杏树药业(苏州)有限公司 | 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途 |
| US20200383984A1 (en) * | 2018-02-08 | 2020-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| AU2019230497B2 (en) | 2018-03-05 | 2021-08-05 | Guangdong Raynovent Biotech Co., Ltd. | Crystal form and salt form of pyridoimidazole compound and preparation method therefor |
| CN110590768B (zh) * | 2018-06-13 | 2021-02-26 | 银杏树药业(苏州)有限公司 | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 |
| CN114340614B (zh) * | 2019-09-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | 一种奥司他韦制剂 |
| CN110967239B (zh) * | 2020-01-02 | 2022-05-10 | 国家地质实验测试中心 | 一种金属铬溶解氧化方法 |
| TW202202500A (zh) * | 2020-07-10 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | Pb2抑制劑及其製備方法和用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| US20250289826A1 (en) * | 2022-04-29 | 2025-09-18 | Tsinghua University | Plpro protein inhibitor, and preparation method and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1730146E (pt) * | 2004-03-30 | 2011-07-11 | Vertex Pharma | Azaindoles úteis como inibidores de jak e outras proteínas quinases |
| PH12015501678B1 (en) | 2009-06-17 | 2022-07-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| KR20130128436A (ko) | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| RU2013132683A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| AU2011343642A1 (en) * | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| CN103702998A (zh) * | 2011-07-05 | 2014-04-02 | 沃泰克斯药物股份有限公司 | 生产氮杂吲哚类的方法和中间体 |
| UA118010C2 (uk) * | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| AU2014348752C1 (en) | 2013-11-13 | 2019-11-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6615755B2 (ja) * | 2013-11-13 | 2019-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インフルエンザウイルスの複製の阻害剤 |
| EP3068434A1 (en) | 2013-11-13 | 2016-09-21 | Vertex Pharmaceuticals Inc. | Formulations of azaindole compounds |
| WO2016020526A1 (en) | 2014-08-08 | 2016-02-11 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
| KR102531340B1 (ko) | 2014-09-08 | 2023-05-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 인플루엔자 바이러스 감염에 사용하기 위한 피롤로피리미딘 |
| CN106854205B (zh) * | 2015-12-09 | 2019-07-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza |
-
2016
- 2016-12-08 CN CN201611123253.3A patent/CN106854205B/zh active Active
- 2016-12-08 CN CN201910228694.7A patent/CN109748915B/zh active Active
- 2016-12-08 SG SG11201804225PA patent/SG11201804225PA/en unknown
- 2016-12-08 EP EP16872423.5A patent/EP3362451B1/en active Active
- 2016-12-08 RU RU2018124993A patent/RU2737190C2/ru active
- 2016-12-08 WO PCT/CN2016/109079 patent/WO2017097234A1/en not_active Ceased
- 2016-12-08 US US15/780,231 patent/US10717732B2/en active Active
- 2016-12-08 AU AU2016368317A patent/AU2016368317B2/en active Active
- 2016-12-08 JP JP2018529614A patent/JP6952695B2/ja active Active
- 2016-12-08 KR KR1020187019477A patent/KR102671350B1/ko active Active
-
2020
- 2020-06-09 US US16/897,256 patent/US11225477B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016368317A1 (en) | 2018-06-07 |
| CN106854205B (zh) | 2019-07-09 |
| KR102671350B1 (ko) | 2024-05-30 |
| EP3362451A4 (en) | 2019-07-03 |
| HK1254668A1 (en) | 2019-07-26 |
| EP3362451A1 (en) | 2018-08-22 |
| US11225477B2 (en) | 2022-01-18 |
| SG11201804225PA (en) | 2018-06-28 |
| US10717732B2 (en) | 2020-07-21 |
| CN106854205A (zh) | 2017-06-16 |
| JP6952695B2 (ja) | 2021-10-20 |
| US20180346463A1 (en) | 2018-12-06 |
| RU2018124993A (ru) | 2020-01-14 |
| WO2017097234A1 (en) | 2017-06-15 |
| CA3005921A1 (en) | 2017-06-15 |
| US20200299294A1 (en) | 2020-09-24 |
| RU2737190C2 (ru) | 2020-11-25 |
| CN109748915B (zh) | 2021-03-26 |
| JP2018536681A (ja) | 2018-12-13 |
| KR20180088466A (ko) | 2018-08-03 |
| AU2016368317B2 (en) | 2019-05-23 |
| EP3362451B1 (en) | 2023-04-12 |
| CN109748915A (zh) | 2019-05-14 |